Ask AI
ESMO 2025 Breast Cancer

CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ESMO Congress

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

European Learners: 1.50 EBAC® CE Credit

Released: December 15, 2025

Expiration: June 14, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Harbeck N, Modi S, Pusztai L, et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Presented at the 2025 European Society for Medical Oncology Congress. Abstr 291O. 
  2. Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann Oncol. 2025;[Epub ahead of print].
  3. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19:115-126.
  4. Huober J, Barrios CH, Niikura N, et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J Clin Oncol. 2022;40:2946-2956.
  5. Geyer CE, Park YH, Shao Z-M, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA1.
  6. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-628.
  7. Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30:2208-2215.
  8. Mayer E, Tolaney SM, Martin M, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA16.
  9. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-529.
  10. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256.
  11. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189-1202.
  12. Imlunestrant [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2025.
  13. Hurvitz SA, Layman RM, Curigliano, G et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA17.
  14. Johnston SR, Martin M, O’Shaughnessy J, et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA13.
  15. Johnston S, Martin M, O'Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2025;[Epub ahead of print].
  16. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  17. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
  18. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
  19. Martin M, Johnston SR, Harbeck N, et al. monarchE: Evaluation of prognostic and predictive value of Ki-67 index pre and post neoadjuvant chemotherapy (NAC) and changes following NAC. Presented at the 2025 European Society for Medical Oncology Congress. Abstr 295MO.
  20. Crown JP, Stroyakovskiy D, Yardley D, et al. Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA14.
  21. Cortés J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217-226.
  22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.5.2025. nccn.org. Accessed November 18, 2025.
  23. Punie K, Kurian AW, Ntalla I, et al. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States. Oncologist. 2025;30:oyaf034.
  24. National Cancer Institute. SEER*Explorer. seer.cancer.gov/statistics-network/explorer/. Accessed December 5, 2025.
  25. Cortés JC, Bardia A, Punie K et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA20.
  26. Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;[Epub ahead of print].
  27. Dent RA, Shao Z, Schmid P et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA21.
  28. Tarantino P, Lee D, Foldi J, et al. Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. J Natl Cancer Inst. 2025;117:2327-2335.
  29. Tolaney S, De Azambuja E, Kalinsky KM, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA109.
  30. De Azambuja E, Schmid P, Kalinsky KM, et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. Presented at the 2025 European Society for Medical Oncology Congress. Abstr LBA22.